Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562610 | 0.83 | SLC2A1 (0.42) | BRD4KDM4ETGFBR1 | |
| SCHEMBL563557 | 0.79 | PTGER4 (0.39) | — | |
| SCHEMBL562158 | 0.76 | STK17B (0.45) | BRD4PKMMAPT | |
| SCHEMBL562959 | 0.76 | CNR1 (0.32) | KCNH2MAPT | |
| SCHEMBL31037652 | 0.75 | KDM4E (0.50) | BRD4KDM4EPKMBCDIN3DGPR119 | |
| SCHEMBL29492699 | 0.74 | IDO1 (0.46) | BRD4KDM4EPKMIDO1TDO2 | |
| SCHEMBL3989909 | 0.74 | IDO1 (0.46) | BRD4KDM4EPKMIDO1TDO2 | |
| SCHEMBL562970 | 0.73 | SLC2A1 (0.43) | BRD4KDM4ETGFBR1 | |
| SCHEMBL22943244 | 0.72 | BRD4 (0.51) | BRD4KDM4EPKMIDO1TDO2 | |
| SCHEMBL31226344 | 0.72 | BRD4 (0.51) | BRD4KDM4EPKMIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. | 2010-06-17 | — | — | US | disclosed |
| EP-1924581-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | Pfizer, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007028129-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | IL4, IL2, IL4I1 | BRD4 193/4885KDM4E 2230/4885PKM 1945/4885 |
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | IL2, IL4, IL4I1 | BRD4 224/4885KDM4E 2272/4885PKM 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.